Ozaki K, Yamamoto T, Ishibashi T, Matsubara T, Nishio M, Aizawa Y
First Department of Internal Medicine, Institute of Nephrology, Niigata University School of Medicine, Japan.
Jpn J Pharmacol. 2001 Feb;85(2):147-54. doi: 10.1254/jjp.85.147.
We investigated the effects of fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on endothelial vasoactive substances using human umbilical vein endothelial cells (HUVECs). Incubation of HUVECs with fluvastatin for 12 h increased endothelial nitric oxide synthase (eNOS) mRNA expression in a concentration-dependent manner (peak, 276 +/- 38%, mean +/- S.D., of the control, at 1.0 microM fluvastatin, P<0.01). In addition, fluvastatin increased eNOS protein production (245 +/- 51% of the control level, P<0.05) as well as nitrite production (165 +/- 35% of the control level, P<0.01). In contrast, incubation of HUVECs with 1.0 microM fluvastatin for 12 h significantly reduced the production of endothelin-1 (ET-1) and preproET-1 mRNA expression in HUVECs (28 +/- 1% and 39 +/- 1% of the control level, respectively, P<0.01). Our results suggest that fluvastatin might be involved in improvement of endothelial function and prevention of the progression of atherosclerosis.
我们使用人脐静脉内皮细胞(HUVECs)研究了3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂氟伐他汀对内皮血管活性物质的影响。用氟伐他汀孵育人脐静脉内皮细胞12小时,可使内皮型一氧化氮合酶(eNOS)mRNA表达呈浓度依赖性增加(在1.0微摩尔/升氟伐他汀时达到峰值,为对照的276±38%,平均值±标准差,P<0.01)。此外,氟伐他汀增加了eNOS蛋白生成(为对照水平的245±51%,P<0.05)以及亚硝酸盐生成(为对照水平的165±35%,P<0.01)。相反,用1.0微摩尔/升氟伐他汀孵育人脐静脉内皮细胞12小时,可显著降低人脐静脉内皮细胞中内皮素-1(ET-1)的生成和前内皮素-1 mRNA表达(分别为对照水平的28±1%和39±1%,P<0.01)。我们的结果表明,氟伐他汀可能参与改善内皮功能和预防动脉粥样硬化进展。